Back to Awarded Treatment Trials
Awarded Trial: 06TGF-996
Grant ID
06TGF-996
Illness
Bipolar Disorder
Primary Drug/Intervention
N-acetylcysteine
Primary Dosage
2 g/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Berk
Sample Size
150
Duration of Study Period for Each Subject
26 weeks
Outcome Measurements
PANSS, MINI PLUS-BP, T.I.M.E, Q-LES-Q (short form), BDRS
Results
N-acetylcysteine (NAC), a precursor of glutathione, was given 1 mg twice daily for 8 wks to 156 BP depressed individuals in an open-label trial, with improvement in symptoms as assessed by MADRS, YMRS, and CGI. After 8 wks, 101 of the patients were randomized to NAC 1 mg twice daily or placebo for a maintenance phase of approximately 7 months. During the maintenance phase, there was no difference in relapse rates between the groups.
Publication
Submitted for publication
Link
N/A
PI Name
Michael Berk
Degree
MD
Center
Mental Health Research Institute
Institution
University of Melbourne
Address
155 Oak Street
City or Town
Parkville
State or Province
Victoria
Zip or Postal Code
3052
Country
Australia
Email Address
mikebe@barwonhealth.org.au